Sweetless'n low LDL-C targets for PCSK9 treatment

Affiliations

¹ Cardiology Division, Department of Specialties in Medicine, Geneva University Hospitals, Switzerland.
² Cardiology Division, Department of Specialties in Medicine, Geneva University Hospitals, Switzerland francois.mach@hcuge.ch.

Editorial

Baris Gencer et al. Eur Heart J. 2015.

. 2015 May 14;36(19):1146-8.

doi: 10.1093/eurheartj/ehv056. Epub 2015 Mar 31.

¹ Cardiology Division, Department of Specialties in Medicine, Geneva University Hospitals, Switzerland.
² Cardiology Division, Department of Specialties in Medicine, Geneva University Hospitals, Switzerland francois.mach@hcuge.ch.

No abstract available

Comment on

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; ODYSSEY COMBO II Investigators. Cannon CP, et al. Eur Heart J. 2015 May 14;36(19):1186-94. doi: 10.1093/eurheartj/ehv028. Epub 2015 Feb 16. Eur Heart J. 2015. PMID: 25687353 Free PMC article. Clinical Trial.